The North America fusion biopsy market size surpassed USD 287.44 million in 2025 and is predicted to reach around USD 626.33 million by 2035, registering a CAGR of 8.1% from 2026 to 2035. Growing due to the rising number of prostate cancer cases and increasing use of advanced image guided biopsy systems.

North America Fusion Biopsy Market Statical Scope

The North America fusion biopsy market is moving toward MRI ultrasound fusion systems and AI assisted imaging which will increase diagnostic precision. Patient preference and clinical outcomes are improving as minimally invasive procedures are used more frequently. The markets growth is also being supported by ongoing investments in cutting edge prostate cancer diagnostics. In addition, rising collaborations between hospitals and diagnostic technology providers are improving workflow integration and patient management. Increasing adoption of cloud-based imaging platforms is also supporting faster diagnosis and better treatment planning across healthcare facilities.

High healthcare costs, early adoption of MRI ultrasound fusion technologies, and robust use of advanced prostate cancer diagnostics are the main drivers. Adoption is being aided by the growing availability of highly qualified urologists and hospitals with cutting edge technology. Demand and procedural accuracy are also being increased by major medical device companies for ongoing innovation. Growing awareness regarding early-stage prostate cancer detection and favorable reimbursement support are further strengthening the regional market. Increasing investments in AI-enabled radiology software are also contributing to market growth.

North America Fusion Biopsy Market Share, By Biopsy Route, 2025 (%)

• Transrectal - Transrectal segment dominated the market in 2025 with a share of 64% motivated by its established use in hospital based prostate biopsy procedures, reduced procedural complexity, and broad clinical preference. Its clinical reliability is further supported by ongoing advancements in imaging-guided techniques. Increasing availability of skilled specialists and advanced diagnostic centers is also supporting segment growth. Expanding use of real time MRI ultrasound fusion technologies is further improving procedural accuracy.
• Transperineal - Transperineal segment emerged as the fastest growing with a share of 36% motivated by decreased risk of infection increased accuracy of cancer detection and a growing trend toward safer biopsy techniques. Uptake is being accelerated by growing physician preference for precision guided sampling. Rising use of MRI fusion technologies is also enhancing procedural efficiency and patient outcomes. Growing clinical accepetance of minimally invasive biopsy methods is further supporting market expansion.

North America Fusion Biopsy Market Share, By End Use, 2025 (%)

• Hospitals - Hospitals dominated the market in 2025 with a share of 58% driven by many new patients in the presence of specialized urology departments and the availability of sophisticated imaging infrastructure. Their dominance is reinforced by the growing use of integrated diagnostic platforms. Increasing investments in AI-enabled imaging solutions are also strengthening hospital adoption. Strong presence of multi specialty healthcare networks is further boosting hospital demand.
• Diagnostic Centers - Diagnostic centers showed notable growth with a share of 27% driven by rising demand for outpatient diagnostics quicker turnaround times and a growing inclination toward specialized imaging services. Market penetration is being further enhanced by the growth of private diagnostic chains. Growth in the segment is also being supported by increased investments in MRI-based diagnostic technologies. Availability of advanced MRI based screening services is also enhancing patient preference.
• Ambulatory Care Centers - Ambulatory care centers recorded steady growth with a share of 15% motivated by more accessible minimally invasive diagnostics, growing outpatient care trends, and cost-effective procedures. Growing demand for same-day procedures is contributing to the expansion. Adoption is also being fueled by a growing emphasis on lessening hospital burden. Improved operational efficiency in ambulatory settings is also contributing to wider adoption.

Competitive Landscape

North America fusion biopsy market competitive landscape is characterized by the strong presence of companies such as GE HealthCare, Philips Healthcare, BK Medical, and Eigen Health. These companies are actively focusing on advanced MRI-ultrasound fusion technologies, AI-assisted imaging solutions, and strategic partnerships with hospitals to improve prostate cancer diagnosis and strengthen their regional market presence. Competition throughout the region is becoming more intense due to increased investments in real time imaging platforms and precision guided biopsy procedures. To improve clinical outcomes and diagnostic efficacy companies are also increasing research collaborations and product commercialization strategies.

Segments Covered in the Report

By Biopsy Route

• Transrectal
• Transperineal

By End Use

• Hospitals
• Diagnostic Centers
• Ambulatory Care Centers